Genincode PLC
LSE:GENI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (28.6), the stock would be worth GBX7.83 (539% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.5 | GBX1.23 |
0%
|
| 3-Year Average | 28.6 | GBX7.83 |
+539%
|
| 5-Year Average | 50.5 | GBX13.81 |
+1 028%
|
| Industry Average | 0 | GBX0 |
-100%
|
| Country Average | 0 | GBX0 |
-100%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
G
|
Genincode PLC
LSE:GENI
|
9.2m GBP | 4.5 | -1.9 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
104.3B USD | 2.8 | 59 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
72.9B EUR | 4.1 | 14.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
74.5B USD | 0 | 12.5 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.2B EUR | 5.6 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.4B EUR | 5.8 | 22.8 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.4B USD | 7 | 21 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21B USD | 6.4 | 24 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 3.4 | 11 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.4B USD | 18.9 | -27.5 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 4.5 | 13.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 664.3 |
Other Multiples
Genincode PLC
Glance View
GENinCode UK Ltd. engages in the risk assessment and prediction of cardiovascular disease. The company is headquartered in Oxford, Oxfordshire. The company went IPO on 2021-07-22. The firm develops patented deoxyribonucleic acid (DNA) risk assessment products which utilize artificial intelligence (AI), bioinformatics and a globally recognized clinical evidence base to provide predictive analysis of a patient’s health risk. The Company’s clinical diagnostic tests cover global disease areas such as cardiovascular, cancer and diabetes.
